3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
9
Phase 1
4
Phase 3
3
Phase 1/2
2
Phase 2/3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms
8
Neoplasm Metastasis
8
Carcinoma, Non-Small-Cell Lung
8
Breast Neoplasms
8
Colorectal Neoplasms
7
Prostatic Neoplasms
6
Urinary Bladder Neoplasms
5
Leukemia, Myeloid, Acute
5
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Lung Neoplasms
4
Glioblastoma
4
Triple Negative Breast Neoplasms
3
Mouth Neoplasms
3
Head and Neck Neoplasms
3
Carcinoma, Transitional Cell
3
Carcinoma, Ovarian Epithelial
3
Uterine Cervical Neoplasms
2
Ureteral Neoplasms
2
Stomatitis
2
Recurrence
2
Oropharyngeal Neoplasms
2
Melanoma
2
Laryngeal Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma
2
COVID-19
2
Brain Neoplasms
2
Adenocarcinoma
2
Interventions
Cyclophosphamide
41
fludarabine
35
Tacrolimus
28
Mycophenolic Acid
27
Whole-Body Irradiation
25
Busulfan
24
fludarabine phosphate
21
Melphalan
19
thymoglobulin
16
Antilymphocyte Serum
16
Methotrexate
13
Thiotepa
12
Stem Cell Transplantation
9
Rituximab
9
Granulocyte Colony-Stimulating Factor
9
Filgrastim
8
Cyclosporine
8
trametinib
7
Sirolimus
7
Nivolumab
5
ruxolitinib
4
merphos
4
Peripheral Blood Stem Cell Transplantation
4
Cytarabine
4
Cord Blood Stem Cell Transplantation
4
Bendamustine Hydrochloride
4
tocilizumab
3
itacitinib
3
fedratinib
3
dabrafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hematologic Neoplasms
×
Standard of Care
×
Clear all
NCT04844866
2026-04-29
DALY 2-EU
Miltenyi Biomedicine GmbH
Phase 2
Recruiting
213 enrolled